News » Visby Medical Appoints Industry Veteran Thomas Prescott as Chairman of the Board

10/28/2021Press Release

Visby Medical Appoints Industry Veteran Thomas Prescott as Chairman of the Board

Thomas Prescott, former president and chief executive officer (CEO) of Align Technology and Cardiac Pathways, will join as the company’s new chairman of the board.

Visby Medical Appoints Industry Veteran Thomas Prescott as Chairman of the Board

SAN JOSE, CA, October 28, 2021 – Visby Medical™, a leading medical diagnostic company, today announced Thomas Prescott, former president and chief executive officer (CEO) of Align Technology and Cardiac Pathways, will join as the company’s new chairman of the board. In his new role, Prescott will lead the Board of Directors and provide strategic counsel on critical growth initiatives for the company.

“I am excited to welcome Tom to the Visby team,” said Visby Medical Founder and CEO Adam de la Zerda. “With decades of experience in multiple leadership positions at innovative medical technology companies, Tom is well-positioned as a very valuable resource for Visby and will help guide our growth. We are very pleased to have him on board.”

Prescott previously served for 13 years as president, CEO and director of Align Technology, a global medical device company and creator of Invisalign, transforming the company from a new public start up to a market leader that established a new category of clear aligner therapy and digital dentistry. He continued to serve as a director of Align until May 2021. Prior to that, he served as president, CEO and director of Cardiac Pathways and held various executive and general management roles at Nellcor Puritan Bennett and GE Medical Systems. Prescott also serves as director and chairman at Earlens Corporation, a board member for The Navy SEAL Foundation, and a trustee at The Naval Postgraduate School Foundation.

“I’m honored to take on this role with an innovative company with proven success delivering the world’s first instrument-free, single-use PCR platform that accurately and rapidly tests for serious infections,” Prescott said. “These advances will be critical in changing the way people are diagnosed and treated for serious infections, and I look forward to working closely with the board to ensure Visby Medical makes a positive impact for all stakeholders.”

Prescott earned his master’s degree from Kellogg Graduate School of Management at Northwestern University and his bachelor’s degree in Civil Engineering from Arizona State University. He is an avid investor, and supports innovation and entrepreneurship at his alma mater, The Fulton School of Engineering at Arizona State University.

About Visby Medical™

Visby Medical is a diagnostics company that is transforming the order of diagnosis and treatment for infectious diseases. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests

Read more articles & insights

04/05/2024Viewpoint

The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

In light of the rising rates of sexually transmitted infections (STIs), urgent care clinics have found themselves at a crucial crossroads. PCR (Polymerase Chain Reaction) testing at the point of care emerges as a potential game-changer.

Read More
The Case for PCR at the Point of Care: Reshaping STI Testing in Urgent Care Clinics

03/14/2024Viewpoint

Understanding the Financial Impact of PCR Point of Care Testing for STIs

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
Understanding the Financial Impact of PCR Point of Care Testing for STIs

03/07/2024Viewpoint

5 Frequently Asked Questions on Implementing PCR into Urgent Care

The adoption of point-of-care polymerase chain reaction (PCR) testing represents a significant leap forward in diagnostic capabilities. With its promise of speed, accuracy, and efficiency, PCR testing technology is setting a new standard in patient care.

Read More
5 Frequently Asked Questions on Implementing PCR into Urgent Care

02/21/2024Press Release

CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test

The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.

Read More
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test